Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Intercalated methotrexate shows more adverse effects in DLBCL treatment than end-use

Publish date:: July 9, 2020

Key clinical point: Intercalated high-dose methotrexate (HD-MTX) was associated with increased toxicity and R-CHOP delays compared to end of treatment (EOT) delivery.

Major finding: Intercalating HD-MTX was the only factor independently associated with R-CHOP delay (HR 2.84 ; P = .001).

Study details: Retrospective analysis of DLCBL patients who received CNS prophylaxis with either i-HD-MTX (n=204) or EOT HD-MTX (n=130).

Disclosures: The abstract contained no conflict information.

Citation:

Wilson M et al. European Hematology Association virtual annual meeting. 2020; Abstract S236.

This Week's Must Reads

Younger adults present with more advanced esophageal adenocarcinoma,

PDAC: Tumor reduction after neoadjuvant therapy may predict postsurgical survival,

Mortality risks rise with age, infections, but not inhibitor status in persons with non-severe hemophilia A,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Must Reads in DLBCL

Synthetic lethality: Triple combination is a viable strategy for B-cell malignancies,

Bispecific antibody odronextamab demonstrates durable complete responses in refractory NHL,

Survey quantifies COVID-19’s impact on oncology,

Sarcopenia is a predictor of overall survival in DLBCL patients,

Mutation tied to central nervous system collapse in DLBCL,